New cancer trial aims to crack the code of who benefits from immunotherapy
NCT ID NCT07431073
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of patients. Participants will receive treatments based on their unique biological profile, not just their cancer type.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can your own immune cells beat advanced cancer?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?